GlaxoSmithKline (now GSK plc) is a British multinational pharmaceutical and biotechnology company formed through the merger of Glaxo Wellcome and SmithKline Beecham. It is headquartered in London and operates globally.
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
IDEAYA Biosciences announced Q4 2025 financial results with $1.05 billion in cash reserves and confirmed 130 progression-free survival events in its Phase 2/3 OptimUM-02 trial of darovasertib for metastatic uveal melanoma, with topline results expected by late March 2026.
The FDA mandated febrile seizure warnings for flu vaccines and rejected Moderna's mRNA flu vaccine application, with a political appointee overruling agency staff despite no safety concerns identified.
The FDA reversed its refusal to review Moderna's mRNA flu vaccine application after the company amended its submission. The agency will now consider full approval for adults 50-64 and accelerated approval for those 65 and older, with a decision expected by August 5, 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07602855 |
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103) |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07602777 |
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07600450 |
A Study of GSK4771261 in Healthy Participants Aged 25 to 55 Years of Age Inclusive |
NOT_YET_RECRUITING | PHASE1 |
| NCT07596199 |
A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women |
NOT_YET_RECRUITING | PHASE3 |
| NCT07596173 |
A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 Years |
NOT_YET_RECRUITING | PHASE3 |
| NCT07591753 |
Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study) |
COMPLETED | |
| NCT07585266 |
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07569081 |
A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07545681 |
A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria |
NOT_YET_RECRUITING | PHASE2 |
| NCT07539857 |
Belimumab to Mobilise Memory B-cells From Secondary Lymhoid Organs to Improve Memory B-cell HLA-specificity Profiling to Support Delisting for Transplant Access in Highly-sensitized |
NOT_YET_RECRUITING | PHASE2 |
